Raltegravir-based Postnatal HIV Prophylaxis Therapy in a Neonate After in Utero Dolutegravir Exposure
| Autor: | Jacobs, T.G., Aerde, K.J. van, Colbers, A.P., Burger, D.M. |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
Microbiology (medical)
Anti-HIV Agents Pyridones lnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4] HIV Infections Piperazines wash-out All institutes and research themes of the Radboud University Medical Center Pregnancy Raltegravir Potassium Oxazines Humans HIV Reports Pregnancy Complications Infectious dolutegravir glucuronide Infant Newborn Antibiotic Prophylaxis neonates Infectious Disease Transmission Vertical lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4] Infectious Diseases Maternal Exposure Pediatrics Perinatology and Child Health Female UGT1A1 raltegravir Heterocyclic Compounds 3-Ring |
| Zdroj: | The Pediatric Infectious Disease Journal Pediatric Infectious Disease Journal, 41, 2, pp. 131-132 Pediatric Infectious Disease Journal, 41, 131-132 |
| ISSN: | 0891-3668 |
| DOI: | 10.1097/INF.0000000000003364 |
| Popis: | We present a case report of a neonate receiving raltegravir-based postnatal HIV prophylaxis after in utero dolutegravir exposure. High levels of raltegravir and dolutegravir can potentially cause bilirubin toxicity as they compete for albumin binding and follow the same metabolic pathway through UGT1A1. This case suggests delaying initiation of raltegravir-based postnatal prophylaxis by 24–48 hours after in utero dolutegravir exposure. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|